Loading stock data…
Hemab Therapeutics Holdings, In (COAG)
$47.31+1.48 (+3.23%)
Market ClosedLast close Jul 24
Hemab Therapeutics Holdings, Inc.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$23.61M↓ | -$16.56M |
| Net Income | -$22.69M↓ | -$15.31M |
Peer Comparison
JNJUNHPFE
Fundamentals
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its pr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.26B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.13%
Volume
Today's trading volume
776,905
Recent News
Biotech IPO Gains Crush AI Listings With Standout 55% Return
(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.2% and
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft. Sorensen said Hemab is pursuing a strategy to build “a multiple product
Hemab Therapeutics IPO Debut Puts COAG And Pipeline Risks In Focus
Hemab Therapeutics Holdings has completed its initial public offering and begun trading on the Nasdaq Global Select Market under the ticker NasdaqGS:COAG. The stock is currently priced at $34.0 per share. The company reports a year to date return of 88.9%. For investors tracking new biotech listings, Hemab Therapeutics Holdings arriving on the Nasdaq Global Select Market puts a fresh ticker on the radar. At a share price of $34.0 and a reported year to date return of 88.9%, NasdaqGS:COAG is...